Multiple indications for everolimus after liver transplantation in current clinical practice

Table 5 Comparison between liver-transplanted patients with de novo tumour receiving everolimus and a historical cohort not receiving mammalian target of rapamycin inhibitors

	Patients receiving everolimusn =13	Historical controls without mTORin = 13	P
Recipient age at transplant (yr)	60.8 ± 5.8	59.5 ± 6.6	NS
Recipient sex (male-female) (%)	77-23	75-25	NS
Indication for LT (%)			NS
Postnecrotic-HCC in cirrhosis	68%	70%	NS
Mean time from LT to diagnosis of de novo tumour (mo)	67 ± 50	65.9 ± 37	NS
Tumour site and histology			NS
Colon ADK	4	4
Prostate ADK	2	2
Lung SCC	1	1
Larynx SCC (4)	2	2
Esophagus SCC(3) + ADK(1)	2	2
Anus SCC	1	1
Breast IDC	1	1
Type of treatment			NS
Surgery ± QT ± RT	10	10
QT ± RT	3	3	NS
Immunosuppression at diagnosis
Cyclosporine-tacrolimus (%)	8-92	24-76	NS
Mean patient survival from diagnosis of tumour (mo)	32.9 ± 15	30.7 ± 20.6	NS

mTORi: Mammalian target of rapamycin inhibitors; LT: Liver transplantation; HCC: Hepatocellular carcinoma; ADK: Adenocarcinoma; SCC: Squamous cell carcinoma; IDC: Infiltrative ductal carcinoma; QT: Chemotherapy; RT: Radiotherapy; NS: No significant.